Pharvaris N.V. - Ordinary Shares, par value Euro 0.12 per share (PHVS)

CUSIP: N69605108

Q2 2026 13F Holders as of 30 Jun 2026

Holder snapshot 6 signals
Share change
-10,795
SEC-reported price per share
$34.58
Number of holders
10
Value change
-$43,193
Number of buys
6
Number of sells
3
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
69,889,980

Security key

N69605108

Report period

Q2 2026

Institutions

10

Top holders

10

Ownership snapshot

Top reported holders of PHVS - Pharvaris N.V. - Ordinary Shares, par value Euro 0.12 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
VIKING GLOBAL INVESTORS LP
Disclosed value leader
GENERAL ATLANTIC, L.P.
Comparable rows
15/15
Latest evidence
30 Jun 2026
13F 13D/G 3/4/5 Lead comparable stake: 5.6% 13D/G row: VIKING GLOBAL INVESTORS LP Showing 1-6 of 15 holder rows.

Quick read

VIKING GLOBAL INVESTORS LP leads the comparable SEC ownership view at 5.6%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens VIKING GLOBAL INVESTORS LP's linked filing trail.
Comparable ownership Top 5
VIKING GLOBAL INVESTORS LP 5.6%
V Cooperatieve U.a. Lsp 4.9%
Venrock Healthcare Capital Partne... 3.8%
Bain Capital Life Sciences Fund, ... 2.5%
Anne Lesage 0.87%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
VIKING GLOBAL INVESTORS LP
13F 13D/G
Company
5.6%
from 13D/G
$103,206,008
3,653,310 shares
31 Mar 2026
V Cooperatieve U.a. Lsp
13D/G
LSP V Cooperatieve U.A.
4.9%
$118,457,225
3,424,609 shares
$0 30 Jun 2026
Venrock Healthcare Capital Partners III, L.P.
13D/G
3.8%
$51,436,214
2,047,620 shares
$0 30 Jun 2025
Bain Capital Life Sciences Fund, L.P.
13D/G
2.5%
$41,020,425
1,640,817 shares
-$5,670,300 31 Dec 2025
Anne Lesage
3/4/5
Chief Early Development
0.87%
$18,282,680
607,526 shares
-$4,758,708 29 Jun 2026
Johannes Gerardus Christiaan Petrus Schikan
3/4/5
Director
0.45%
$11,186,096
315,167 shares
-$2,625,672 29 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
10
Shares
84,307
Rows available
10
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q3 2025 Across Filers

Q3 2025 holders
83
Q2 2026 holders
10
Holder diff
-73
Investor Q3 2025 Shares Q2 2026 Shares Share Diff Share Chg % Q3 2025 value Q2 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .